Express News | SINOPHARM and SINO BIOPHARM signed a deep global strategy cooperation agreement.

BreakingsDec 20 09:44

The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."

In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.

cls.cnDec 19 22:27

Sino Biopharm Cleared to Submit Marketing Application for New Indication of Tumor Drug

MT NewswiresDec 19 18:17

Sino Biopharmaceutical's Cancer Drug Shows Positive Results in Clinical Trials

MT NewswiresDec 19 17:08

[Hong Kong Stock Connect] China National Pharmaceutical Group (01177): Beimu Subei monoclonal antibody injection combined with Anlotinib hydrochloride capsules has received written approval from CDE to submit a listing application.

The Jinwu Financial News reports that China National Pharmaceutical Group (01177) has announced that the group's independently developed Category 1 Innovative Drug, Bemosituzumab injection combined with Anlotinib hydrochloride capsules, has communicated with the Drug Evaluation Center (CDE) of the National Medical Products Administration (NMPA) about the new indication for advanced alveolar soft part sarcoma (ASPS) and has received written consent from the CDE to submit a market application. The group will submit the market application soon. ASPS will be the 12th indication for which Anlotinib is about to apply for listing, and the 5th indication for Bemosituzumab, which is expected to bring new hope to ASPS patients.

Jinwu Finance NewsDec 19 16:53

China National Pharmaceutical Group (01177.HK) will submit a market application for the ASPS indication of Innovative Drugs.

Zhongsheng Pharmaceutical (01177.HK) announced that the group has independently developed a Class 1 Innovative Drug, Bemotuzumab Injection, in combination with Anlotinib Hydrochloride Capsules, and has communicated with the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) regarding the application for market approval for the new indication of late-stage alveolar soft part sarcoma (ASPS). Written consent has been obtained from the CDE to submit the market application. The group will submit the market application in the near future. ASPS is the 12th indication for which Anlotinib is about to be applied for market approval, and the 5th indication for which Bemotuzumab is about to be applied for market approval, which is expected to provide new treatment options for ASPS patients. Bemotuzumab.

AASTOCKSDec 19 16:39